GILD Quote, Financials, Valuation and Earnings

Amgen has a net margin of 16.61% compared to Gilead Sciences's net margin of 33.28%. Gilead Sciences's return on equity of 0.64% beat Amgen's return on equity of 65.35%.

Gilead Sciences has a consensus price target of $98.92, signalling upside risk potential of 6.86%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.42%. Given that Amgen has higher upside potential than Gilead Sciences, analysts believe Amgen is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.175, which suggesting that the stock is 82.499% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.

Gilead Sciences has a quarterly dividend of $0.77 per share corresponding to a yield of 3.33%. Amgen offers a yield of 3.42% to investors and pays a quarterly dividend of $2.25 per share. Gilead Sciences pays 67.24% of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences quarterly revenues are $7.5B, which are smaller than Amgen quarterly revenues of $8.5B. Gilead Sciences's net income of $1.3B is lower than Amgen's net income of $2.8B. Notably, Gilead Sciences's price-to-earnings ratio is 1,028.56x while Amgen's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.09x versus 4.37x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 16.61% compared to Gilead Sciences's net margin of 8.48%. Gilead Sciences's return on equity of 0.64% beat Eli Lilly and's return on equity of 66.4%.

Gilead Sciences has a consensus price target of $98.92, signalling upside risk potential of 6.86%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Eli Lilly and has higher upside potential than Gilead Sciences, analysts believe Eli Lilly and is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.175, which suggesting that the stock is 82.499% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Gilead Sciences has a quarterly dividend of $0.77 per share corresponding to a yield of 3.33%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Gilead Sciences pays 67.24% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Gilead Sciences quarterly revenues are $7.5B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Gilead Sciences's net income of $1.3B is higher than Eli Lilly and's net income of $970.3M. Notably, Gilead Sciences's price-to-earnings ratio is 1,028.56x while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.09x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 16.61% compared to Gilead Sciences's net margin of 18.95%. Gilead Sciences's return on equity of 0.64% beat Merck &'s return on equity of 29.26%.

Gilead Sciences has a consensus price target of $98.92, signalling upside risk potential of 6.86%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 31.29%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.175, which suggesting that the stock is 82.499% less volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Gilead Sciences has a quarterly dividend of $0.77 per share corresponding to a yield of 3.33%. Merck & offers a yield of 3.18% to investors and pays a quarterly dividend of $0.81 per share. Gilead Sciences pays 67.24% of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

Gilead Sciences quarterly revenues are $7.5B, which are smaller than Merck & quarterly revenues of $16.7B. Gilead Sciences's net income of $1.3B is lower than Merck &'s net income of $3.2B. Notably, Gilead Sciences's price-to-earnings ratio is 1,028.56x while Merck &'s PE ratio is 20.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.09x versus 3.95x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 16.61% compared to Gilead Sciences's net margin of 25.23%. Gilead Sciences's return on equity of 0.64% beat Pfizer's return on equity of 4.63%.

Gilead Sciences has a consensus price target of $98.92, signalling upside risk potential of 6.86%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Pfizer has higher upside potential than Gilead Sciences, analysts believe Pfizer is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.175, which suggesting that the stock is 82.499% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Gilead Sciences has a quarterly dividend of $0.77 per share corresponding to a yield of 3.33%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Gilead Sciences pays 67.24% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Gilead Sciences quarterly revenues are $7.5B, which are smaller than Pfizer quarterly revenues of $17.7B. Gilead Sciences's net income of $1.3B is lower than Pfizer's net income of $4.5B. Notably, Gilead Sciences's price-to-earnings ratio is 1,028.56x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.09x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.